席志超,副研究员
基本信息
办公电话:021-51322301
电子邮箱:xizhichaohaerbin@163.com
通讯地址:上海市浦东新区蔡伦路1200号
招生专业
研究方向:中药抗肿瘤药理
院系名称:伟德国际官方入口
学位类型:学术学位
专业名称:中药学/100800
2006.09-2010.07, 黑龙江中医药大学, 中药学, 学士
2010.09-2016.07, 上海中医药大学, 中药学, 博士
2012.09-2013.03, 悉尼大学, 访问学者
任职经历
2016.07-2018.06,上海中医药大学,伟德国际官方入口,博士后
2018.07-2019.12,上海中医药大学,伟德国际官方入口,助理研究员
2020.01-今,上海中医药大学,伟德国际官方入口,副研究员
获项及荣誉
长期从事中药药理作用及机制研究,重点研究领域为恶性肿瘤,单纯疱疹病毒及脑血管疾病的中药防治作用及机理研究。发表学术论文40篇,已授权国家发明专利5项,参与编写教材及著作四部。主持并完成国家自然科学基金等科研项目,参与多个国家级和省部级课题。获得高等学校科学研究优秀成果奖(科学技术)二等奖(第三负责人)。
任中华中医药学会药理实验分会副秘书长、上海市药理学会中药专委会副主任委员兼秘书长、上海市药学会中药专委会秘书长和世界中联中医药抗病毒研究专业委员会理事等。担任Acta Materia Medica和Chinese Medicine杂志的青年编委,担任Frontiers in Cell and Developmental Biology和Frontiers in Oncology等杂志的审稿编辑。
承担科研项目情况
国家自然科学基金,天然化合物Guttiferone K调节线粒体核糖体蛋白选择性杀死静止期前列腺癌细胞的机理研究(81803571),主持
中国博士后基金,藤黄属PPAPs类化合物抑制前列腺癌复发的活性研究(2016M601641),主持
上海中医药大学科技发展基金,紫檀芪抑制静止期癌细胞再激活预防前列腺癌复发的作用机理(23KFL041),主持
主要代表性成果
Matthew Wong*, Yuting Sun*, Zhichao Xi*, Giorgio Milazzo, Rebecca C Poulos, Christoph Bartenhagen et al. JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. Nature Communications. 2019, 10(1): 3319. (IF=16.6)
Rongchen Dai*, Mengfan Liu*, Xincheng Xiang, Zhichao Xi#, Hongxi Xu#. Osteoblasts and osteoclasts: an important switch of tumour cell dormancy during bone metastasis. Journal of Experimental & Clinical Cancer Research. 2022,41(1):316. (IF=11.3)
Jiling Feng*, Zhichao Xi*, Xue Jiang, Yang Li, Wan Najbah Nik Nabil, Mengfan Liu, Zejia Song, Xiaoqiong Chen, Hua Zhou, Qihan Dong#, Hongxi Xu#. Saikosaponin A enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy. Cancer Letters. 2023,554:216011. (IF=9.7)
Zhichao Xi, Mu Yao, Yang Li, Chanlu Xie, J Holst, Tao Liu, Shuangfan Cai, Yuanzhi Lao, Hongsheng Tan, Hongxi Xu#, Qihan Dong#. Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. Cell Death & Disease. 2016,7(6): e2252. (IF=9)
Yang Li*, Zhichao Xi*, Xiaoqiong Chen, Shuangfan Cai, Chen Liang, Zhen Wang, Yingyi Li, Hongsheng Tan, Yuanzhi Lao#, Hongxi Xu#. Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways. Cell Death & Disease. 2018, 9(5):538. (IF=9)
Hangui Ren*, Rongchen Dai*, Yinchen Chen, Zhichao Xi#, Hongxi Xu#. How ginseng regulates autophagy: Insights from multistep process. Biomedicine & Pharmacotherapy. 2023,158:114139. (IF=7.5)
Wan Najbah Nik Nabil*, Zhichao Xi*, Zejia Song, Lei Jin, Xu Dong Zhang, Hua Zhou, Paul De Souza, Qihan Dong#, Hongxi Xu#. Towards a Framework for Better Understanding of Quiescent Cancer Cells. Cells. 2021,10(3):562. (IF=6)
Mengfan Liu*, Xueyang Sun*, Boya Chen, Rongchen Dai, Zhichao Xi#, Hongxi Xu#. Insights into Manganese Superoxide Dismutase and Human Diseases. International Journal of Molecular Sciences. 2022,23(24):15893. (IF=5.6)
Rongchen Dai*, Mengfan Liu*, Xincheng Xiang, Yang Li, Zhichao Xi#, Hongxi Xu#. OMICS Applications for Medicinal Plants in Gastrointestinal Cancers: Current Advancements and Future Perspectives. Frontiers in Pharmacology. 2022,13:842203. (IF=5.6)
Xue Jiang*, Yang Li*, Jiling Feng, Wan Najbah Nik Nabil, Rong Wu, Yue Lu, Hua Liu, Zhi-chao Xi#, Hong-xi Xu#. Safranal prevents prostate cancer recurrence by blocking the re-activation of quiescent cancer cells via downregulation of S-phase kinase associated protein 2. Frontiers in Cell and Developmental Biology. 2020, 8:598620. (IF=5.5)